Research ExplorerPublicationsEfficacy of Liposomal Cytarabine in the Treatment of Leptome...

Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer

Standard

Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer. / Laakmann, Elena; Witzel, Isabell; Müller, Volkmar.

In: BREAST CARE, Vol. 12, No. 3, 07.2017, p. 165-167.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laakmann, E, Witzel, I & Müller, V 2017, 'Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer', BREAST CARE, vol. 12, no. 3, pp. 165-167. https://doi.org/10.1159/000464400

APA

Laakmann, E., Witzel, I., & Müller, V. (2017). Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer. BREAST CARE, 12(3), 165-167. https://doi.org/10.1159/000464400

Vancouver

Laakmann E, Witzel I, Müller V. Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer. BREAST CARE. 2017 Jul;12(3):165-167. https://doi.org/10.1159/000464400

Bibtex

@article{d11d929fb04b4370bf34b8ffbbaa0da6,
title = "Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer",
abstract = "BACKGROUND: Breast cancer is one of the most frequent causes of leptomeningeal metastasis (LM) among solid tumors in adults. The prognosis of patients with LM is poor. A treatment option is the intrathecal administration of liposomal cytarabine.CASE REPORTS: The first case represents a 53-year-old woman with LM of breast cancer. A neurological response was achieved shortly after the start of the multimodal treatment including intrathecal liposomal cytarabine. The response duration reached 79 days. The second case represents a 48-year-old woman with LM of breast cancer treated with intrathecal liposomal cytarabine as a part of a multimodal treatment approach. A neurological response was achieved in the first 2 weeks of treatment and is still lasting after 18 months.CONCLUSION: These cases suggest that a rapid response to a prompt start of treatment with intrathecal liposomal cytarabine in patients with LM of breast cancer is feasible. In 1 case an extremely long progression-free survival (18+ months) was achieved. The cases support the efficacy of liposomal cytarabine in the management of LM in breast cancer patients as a part of a multimodal treatment approach and underline the need for further investigations in this specific cohort.",
keywords = "Journal Article",
author = "Elena Laakmann and Isabell Witzel and Volkmar M{\"u}ller",
year = "2017",
month = jul,
doi = "10.1159/000464400",
language = "English",
volume = "12",
pages = "165--167",
journal = "BREAST CARE",
issn = "1661-3791",
publisher = "S. Karger AG",
number = "3",

}

RIS

TY - JOUR

T1 - Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer

AU - Laakmann, Elena

AU - Witzel, Isabell

AU - Müller, Volkmar

PY - 2017/7

Y1 - 2017/7

N2 - BACKGROUND: Breast cancer is one of the most frequent causes of leptomeningeal metastasis (LM) among solid tumors in adults. The prognosis of patients with LM is poor. A treatment option is the intrathecal administration of liposomal cytarabine.CASE REPORTS: The first case represents a 53-year-old woman with LM of breast cancer. A neurological response was achieved shortly after the start of the multimodal treatment including intrathecal liposomal cytarabine. The response duration reached 79 days. The second case represents a 48-year-old woman with LM of breast cancer treated with intrathecal liposomal cytarabine as a part of a multimodal treatment approach. A neurological response was achieved in the first 2 weeks of treatment and is still lasting after 18 months.CONCLUSION: These cases suggest that a rapid response to a prompt start of treatment with intrathecal liposomal cytarabine in patients with LM of breast cancer is feasible. In 1 case an extremely long progression-free survival (18+ months) was achieved. The cases support the efficacy of liposomal cytarabine in the management of LM in breast cancer patients as a part of a multimodal treatment approach and underline the need for further investigations in this specific cohort.

AB - BACKGROUND: Breast cancer is one of the most frequent causes of leptomeningeal metastasis (LM) among solid tumors in adults. The prognosis of patients with LM is poor. A treatment option is the intrathecal administration of liposomal cytarabine.CASE REPORTS: The first case represents a 53-year-old woman with LM of breast cancer. A neurological response was achieved shortly after the start of the multimodal treatment including intrathecal liposomal cytarabine. The response duration reached 79 days. The second case represents a 48-year-old woman with LM of breast cancer treated with intrathecal liposomal cytarabine as a part of a multimodal treatment approach. A neurological response was achieved in the first 2 weeks of treatment and is still lasting after 18 months.CONCLUSION: These cases suggest that a rapid response to a prompt start of treatment with intrathecal liposomal cytarabine in patients with LM of breast cancer is feasible. In 1 case an extremely long progression-free survival (18+ months) was achieved. The cases support the efficacy of liposomal cytarabine in the management of LM in breast cancer patients as a part of a multimodal treatment approach and underline the need for further investigations in this specific cohort.

KW - Journal Article

U2 - 10.1159/000464400

DO - 10.1159/000464400

M3 - SCORING: Journal article

C2 - 28785184

VL - 12

SP - 165

EP - 167

JO - BREAST CARE

JF - BREAST CARE

SN - 1661-3791

IS - 3

ER -